Acrivon Therapeutics (ACRV) EPS (Basic) Growth (1y) (2022 - 2026)
Acrivon Therapeutics (ACRV) EPS (Basic) Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 322.67% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 96.41% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -16.29% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -147.33% |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.90% |
| Mar 31, 2026 | 12.95% |
| Dec 31, 2025 | 27.03% |
| Sep 30, 2025 | 40.80% |
| Jun 30, 2025 | 18.10% |
| Mar 31, 2025 | 44.33% |
| Dec 31, 2024 | 22.12% |
| Sep 30, 2024 | 30.97% |
| Jun 30, 2024 | 54.09% |
| Mar 31, 2024 | 25.11% |
| Dec 31, 2023 | 61.09% |
| Sep 30, 2023 | 85.70% |
| Jun 30, 2023 | 52.39% |
| Mar 31, 2023 | 60.70% |
| Dec 31, 2022 | 30.98% |
| Sep 30, 2022 | -493.42% |